Mushrooms Inc. Validates Mycelium-Based Infection Detection Technology and Reassesses Strategic Direction

Mushrooms Inc. announced successful early-stage validation of its mycelium-based infection detection technology and completion of beta testing for its MycoLab.ai research platform. These developments mark significant advancement in the MycoLabX platform's development and have prompted the company to reassess strategic options regarding its previously announced transaction with SecurCapital Corp.

The company achieved a technical milestone through prototype testing that demonstrated visible color-change response when mycelium-based films were exposed to bacterial activity. This confirmation of the core sensing mechanism represents successful early-stage proof of concept for the patent-pending technology. The observed biological response validates the approach using engineered mycelium-derived biomaterials designed to react to bacterial presence and provide visual infection indication. Following this validation, the company is preparing for expanded testing and third-party validation initiatives, including evaluation pathways with leading U.S. research and defense-related institutions.

This successful validation represents a key milestone toward developing next-generation biomaterials capable of detecting infection in wound care, medical monitoring, and related healthcare applications. The intellectual property covering these technologies is currently under review with the United States Patent and Trademark Office as part of the company's ongoing patent application process. Management believes this demonstration, combined with planned next-phase validation, represents meaningful advancement toward commercialization and significantly enhances the platform's long-term value potential.

Additionally, the MycoLab.ai mycology research platform has successfully completed beta testing, demonstrating effectiveness of its AI-driven interface in accessing and organizing foundational scientific data. The platform incorporates advanced artificial intelligence tools to assist researchers, growers, product developers, and scientists in identifying relevant insights and accelerating practical application of mycological research. MycoLabX combines this proprietary data and AI capability with broader biomaterials and applied fungal biotechnology initiatives, creating a unified ecosystem intended to support innovation, product development, and commercialization.

Following recent advancements within the MycoLabX platform, including key technical validation milestones and platform progress, Mushrooms Inc. conducted a reassessment of its strategic positioning and long-term objectives. Both Mushrooms Inc. and SecurCapital Corp mutually agreed that the originally contemplated transaction structure is being reevaluated and may be modified to better align with the company's current strategic position. The companies are not proceeding under the originally contemplated structure at this time and are instead evaluating alternative structures and strategic opportunities that align with the company's evolving strategic position.

Mushrooms Inc. will continue advancing development of the MycoLabX platform, including next phase testing of its infection-detection biomaterials and launch of the MycoLab.ai research platform. To support these activities, the company is actively evaluating strategic funding opportunities to accelerate validation, scale testing, and advance the biomaterials platform toward commercialization. Management believes these developments significantly strengthen the company's position in emerging mycelium-based biomaterials, biomedical sensing technologies, and fungal biotechnology more broadly. The company believes recent technical validation and progress create new opportunities to pursue strategic partnerships, research collaborations, and investment aligned with the expanded potential of the platform.